Asset Management One Co. Ltd. Grows Stock Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Asset Management One Co. Ltd. boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 5.2% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 936,060 shares of the biopharmaceutical company's stock after buying an additional 46,208 shares during the quarter. Asset Management One Co. Ltd.'s holdings in Bristol Myers Squibb were worth $57,090,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Pinney & Scofield Inc. purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter worth about $25,000. Park Square Financial Group LLC bought a new position in Bristol Myers Squibb during the 4th quarter valued at approximately $26,000. Fairway Wealth LLC purchased a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $28,000. Transce3nd LLC bought a new stake in shares of Bristol Myers Squibb in the 4th quarter worth approximately $28,000. Finally, Global Wealth Strategies & Associates increased its stake in shares of Bristol Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 275 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Activity at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the firm's stock in a transaction dated Friday, April 25th. The stock was purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president now directly owns 83,513 shares of the company's stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.09% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on BMY shares. Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Piper Sandler started coverage on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price on the stock. UBS Group decreased their price target on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. William Blair restated a "market perform" rating on shares of Bristol Myers Squibb in a report on Friday, April 25th. Finally, Jefferies Financial Group reduced their target price on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $58.00.

Bristol Myers Squibb Stock Down 0.6%

Shares of NYSE BMY traded down $0.30 during trading on Wednesday, reaching $46.73. The company had a trading volume of 8,882,940 shares, compared to its average volume of 12,958,726. Bristol Myers Squibb Company has a 12-month low of $39.35 and a 12-month high of $63.33. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. The business's 50-day moving average is $48.06 and its 200 day moving average is $54.16. The stock has a market cap of $95.10 billion, a PE ratio of 17.50, a P/E/G ratio of 1.39 and a beta of 0.38.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. Bristol Myers Squibb's revenue for the quarter was down 5.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($4.40) EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be given a $0.62 dividend. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.31%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.